Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cornel Popovici

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
European Journal of Medical Genetics|October 11, 2020
National recommendations of the French Genetics and Cancer Group - Unicancer on the modalities of multi-genes panel analyses in hereditary predispositions to tumors of the digestive tractMarion Dhooge, Stéphanie Baert-Desurmont, Carole Corsini, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2021
TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patientsCecile Vicier, Patrick Sfumato, Nicolas Isambert, et al.
EMBO Molecular Medicine|February 18, 2011
ZNF703 gene amplification at 8p12 specifies luminal B breast cancerFabrice Sircoulomb, Nathalie Nicolas, Anthony Ferrari, et al.
Cancers|May 14, 2022
Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical TrialEmilien Billon, Gwenaelle Gravis, Arnaud Guille, et al.
Nature Communications|March 4, 2025
Inhibition of the STAT3/Fanconi anemia axis is synthetic lethal with PARP inhibition in breast cancerCelia D Rouault, Lucile Bansard, Elena Martínez-Balsalobre, et al.
Oncotarget|October 22, 2016
Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective studyAnthony Gonçalves, François Bertucci, Arnaud Guille, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 29, 2026
Cancer risks for ATM variant heterozygotesYue Jiao, David E Goldgar, Dorothée Le Gal, et al.
Genome Medicine|May 19, 2021
Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trialFrançois Bertucci, Anthony Gonçalves, Arnaud Guille, et al.
Cancers|August 7, 2021
TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel TestingFabienne Lesueur, Séverine Eon-Marchais, Sarah Bonnet-Boissinot, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2022
Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the diseaseYue Jiao, Thérèse Truong, Séverine Eon-Marchais, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
European Journal of Medical Genetics|October 11, 2020
National recommendations of the French Genetics and Cancer Group - Unicancer on the modalities of multi-genes panel analyses in hereditary predispositions to tumors of the digestive tractMarion Dhooge, Stéphanie Baert-Desurmont, Carole Corsini, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2021
TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patientsCecile Vicier, Patrick Sfumato, Nicolas Isambert, et al.
EMBO Molecular Medicine|February 18, 2011
ZNF703 gene amplification at 8p12 specifies luminal B breast cancerFabrice Sircoulomb, Nathalie Nicolas, Anthony Ferrari, et al.
Cancers|May 14, 2022
Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical TrialEmilien Billon, Gwenaelle Gravis, Arnaud Guille, et al.
Nature Communications|March 4, 2025
Inhibition of the STAT3/Fanconi anemia axis is synthetic lethal with PARP inhibition in breast cancerCelia D Rouault, Lucile Bansard, Elena Martínez-Balsalobre, et al.
Oncotarget|October 22, 2016
Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective studyAnthony Gonçalves, François Bertucci, Arnaud Guille, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 29, 2026
Cancer risks for ATM variant heterozygotesYue Jiao, David E Goldgar, Dorothée Le Gal, et al.
Genome Medicine|May 19, 2021
Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trialFrançois Bertucci, Anthony Gonçalves, Arnaud Guille, et al.
Cancers|August 7, 2021
TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel TestingFabienne Lesueur, Séverine Eon-Marchais, Sarah Bonnet-Boissinot, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2022
Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the diseaseYue Jiao, Thérèse Truong, Séverine Eon-Marchais, et al.
Pageof 6